Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: Implications for risk of early-onset breast cancer in young women from hereditary breast cancer families

British Journal of Cancer

Volumn 92, Issue 5, 2005, Pages 857-866

  Jernstrom H ^a   Sandberg, T ^a   Bageman E ^a   Borg, A ^a   Olsson, H ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BRCA1; Breast volume; IGF 1 levels; IGF1 genotype; Premenopausal breast cancer; Prospective cohort study

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN C;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SIZE; CANCER RISK; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; MUTATIONAL ANALYSIS; NORMAL HUMAN; NULLIPARA; ONCOGENE; ONSET AGE; ORGAN SIZE; PENETRANCE; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT;

AGE OF ONSET; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE-FREE SURVIVAL; DNA PRIMERS; FAMILY; FEMALE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PARITY; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; REGISTRIES; SWEDEN;

EID: 16244381377     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602389     Document Type: Article

References (48)

1. Abramovitcha S, Glasera T, Ouchib T, Werner H (2003) BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett 541: 149-154
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130
3. Arends N, Johnston L, Hokken-Koelega A, van Duijn C, de Ridder M, Savage M, Clark A (2002) Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 87: 2720-2724
4. Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124: 620-629
5. Beral V, Reeves G (1993) Childbearing, oral contraceptive use, and breast cancer (letter) (see comments). Lancet 341: 1102
6. Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ (2001) Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Curr Oncol Rep 3: 314-321
7. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60: 3744-3748
8. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727
9. DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, Probst-Hensch NM (2003) IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 88: 277-282
10. Dickson R (1996) Biochemical control of breast development. In Diseases of the Breast Harris JR, Lippman ME, Morrow M, Hellman S (eds) pp 15-25. Philadelphia: Lippincott-Raven
11. Dupont WD, Page DL (1987) Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 125: 769-779
12. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271
13. Egan KM, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Baron JA, Willett WC, Stampfer MJ, Trichopoulos D (1999) The relation of breast size to breast cancer risk in postmenopausal women (United States). Cancer Causes Control 10: 115-118
14. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M and the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
15. Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3: 298-302
16. Hamilton AS, Mack TM (2003) Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med 348: 2313-2322
17. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351: 1393-1396
18. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppala M (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98: 2612-2615
19. Hartmann BW, Laml T, Kirchengast S, Albrecht AE, Huber JC (1998) Hormonal breast augmentation: prognostic relevance of insulin-like growth factor-I. Gynecol Endocrinol 12: 123-127
20. Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 862-867
21. Hovey RC, Trott JF, Vonderhaar BK (2002) Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia 7: 17-38
22. Jernström H, Barrett-Connor E (1999) Obesity, weight change, fasting insulin, pro-insulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: The Rancho Bernardo Study. J Women's Health 8: 1265-1272
23. Jernström H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA (2001a) Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for pre-menopausal breast cancer risk. Mol Genet Metab 72: 144-154
24. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M (2001b) Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10: 377-384
25. Jernström H, Johannsson O, Borg Å, Ivarsson H, Olsson H (1998) BRCA1-positive patients are small for gestational age compared with their unaffected relatives. Eur J Cancer 34: 368-371
26. Jernström H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber M, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet J-S, Narod SA (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354: 1846-1850
27. Jernström H, Olsson H (1994) Suppression of plasma insulin-like growth factor-1 levels in healthy, nulliparous, young women using low dose oral contraceptives. Gynecol Obstetr Invest 38: 261-265
28. Jernström H, Olsson H (1997) Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years. Am J Epidemiol 145: 571-580
29. Kao PC, Matheny Jr AP, Lang CA (1994) Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 78: 310-312
30. LeRoith D, Roberts CTJ (2003) The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137
31. Marcus PM, Baird DD, Millikan RC, Moorman PG, Qaqish B, Newman B (1999) Adolescent reproductive events and subsequent breast cancer risk. Am J Public Health 89: 1244-1247
32. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodoch LA (1995) The developmental pattern of Brca 1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11: 17-26
33. McCarthy TL, Ji C, Shu H, Casinghino S, Crothers K, Rotwein P, Centrella M (1997) 17beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures. J Biol Chem 272: 18132-18139
34. Missmer SA, Haiman CA, Hunterk DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE (2002) A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100: 332-336
35. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernström H, Sun P, Brunet JS (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773-1779
36. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, DiAugustine RP, Barrett JC, Afshari CA, Dunn SE (2002) Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 4: 204-217
37. Olsson H (1990) Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill? Med Oncol Tumor Pharmacother 7: 61-64
38. Olsson H, Möller T, Ranstam J (1989) Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 81: 1000-1004
39. Rajan JV, Wang M, Marquis ST, Chodosh LA (1996) Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 93: 13078-13083
40. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM, Lamberts SW (2003) A polymorphism in the IGF-1 gene influences the age-related decline in circulating total IGF-1 levels. Eur J Endocrinol 148: 171-175
41. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83: 2286-2290
42. Rotwein P, Pollock KM, Didier DK, Krivi GG (1986) Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J Biol Chem 261: 4828-4832
43. Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76: 1005-1026
44. Streuwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. N Engl J Med 336: 1401-1408
45. Thurfjell E, Hsieh CC, Lipworth L, Ekbom A, Adami HO, Trichopoulos D (1996) Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev 5: 37-41
46. Tonin P, Ghadirian P, Phelan C, Lenoir GM, Lynch HT, Letendre F, Belanger D, Monte M, Narod SA (1995) A large multisite cancer family is linked to BRCA2. J Med Genet 32: 982-984
47. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50: 637-642
48. Weber JL, May PE (1989) Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 44: 388-396